Acute Lymphoblastic Leukemia In Adults Survival Rate

Acute Lymphoblastic Leukemia In Adults Survival Rate

Acute lymphoblastic leukemia in adults survival rate - Acute lymphoblastic leukemia (ALL) accounts for 20% of all acute leukemia that occurs in patients older than 20 years and each year affects approximately 2 persons in 100 000 patients in the United States. Despite its relative shortcomings, arises a great interest in it, that ALLterus has a high mortality rate when left not treated, and because of the biological and therapeutic lessons obtained in the study of this disease.

Acute lymphoblastic leukemia (ALL) is a type of blood cancer. Also known as acute lymphocytic leukemia or acute lymphocytic leukemia, it is the most common type of leukemia in adults. Acute lymphoblastic leukemia in adults survival rate - Here's what you need to know about symptoms, prognosis, survival rates and the treatment of ALL.

Successful therapy in childhood ALL also provokes a search for the same extent of cure in adults, and that using chemotherapy with the intensive removal of induction and the concept of consolidation and maintenance therapy after remission. So far, the treatment for ALL adults led to lower rates of remission, but more promises have completed 75% to 90% and 3-year-survival rate of 25% to 50%. In addition, recent research has contributed to understanding biology. ALL and prognostic factor. The important thing is that now there is specific therapy focused on relatively homogeneous subgroups of ALL. Parallel improvements in supportive care, such as prophylactic antibiotics, appropriate use of transplants of bone marrow, and maybe the use of hematopoietic growth factors also have contributed to better survival rates.

List of bad prognostic factors, which have a great impact on the complete degree of remission, duration of remission and survival in patients with ALL. In multivariate analysis, patients with the number of white blood cells> 30 000 / µL significantly shorter time to remission than patients with a lower number of leukocytes. Acute lymphoblastic leukemia in adults survival rate - However, in patients with ALL T cells have extreme leukocytosis negative effect on the results.

The age group older than 60 years are more harmful characteristics. Duration remise and overall survival decreased in almost every study for ALL adults with increasing age group of patients. Fewer prognostic factors or significant for certain treatment regimens is a percentage of the circulating blast cells; the level of involvement of the bone marrow; the presence of hepatomegaly, splenomegaly, or lymphadenopathy; the level of lactate dehydrogenase; the Involvement of the central nervous system (CNS) during the presentation; and the time required to achieve complete remission.

Acute Lymphoblastic Leukemia Survivors Treatment

Acute lymphoblastic leukemia (ALL) is really a group of related diseases or subtypes. Therefore, your choice of treatment depends on the subtype and other factors. You can have more than one type of treatment. It includes:

1. Chemotherapy, the use of anti-cancer drugs in combination, generally over a period of several years. Among the agents used for ALL include cyclophosphamide to vincristine.

2. Bone marrow transplant, which involves the use of high doses of chemotherapy and possibly radiation followed by bone-forming stem cells. Stem cells usually come from donors, or less probably from your own bone marrow or peripheral blood. If you can't tolerate the high doses of chemotherapy and radiation, lower doses may be used with the "mini-transplant".

3. Radiation therapy, the use of radiation energy with high energy to kill cancer cells; It is not often used for all, but can be used to treat leukemia in the brain or bone, for example, or before stem cell transplantation.

4. Targeted therapies, drugs that target certain parts of cancer cells and tend to have less or worse side effects than chemotherapy; examples include blinatumomab (Blincyto), dasatinib (Sprycel), imatinib (Gleevec), and nilotinib (Tasigna), ponatinib (Iclusig), which attack cells with the Philadelphia chromosome.

Remission intensive chemotherapy followed by post-recovery consolidation and maintenance therapy achieved a complete remission of 75% to 90% and 3-year survival of 25% to 50% of adult patients with acute lymphoblastic leukemia (ALL). This result, although promising, is still less favorable than the outcome for all children.

However, a number of new experimental and clinical approaches promises to increase the rate of cure. Acute lymphoblastic leukemia in adults survival rate - Also, begin to appear specific therapy directed at the subgroup with high-risk ALL. Location of particular chromosomal variations from the norm in the finding to distinguish patients in danger of neglecting to accomplish reduction, and also the individuals who as a rule have a shorter ailment free interim, medium, or stretched out after fruitful acceptance of abatement.